GEMINI: Entyvio safety profile favorable in long-term use

The safety profile of Entyvio remained favorable through 8 years of use in patients with inflammatory bowel disease, according to results from the GEMINI long-term safety study.Edward V. Loftus, MD, professor of medicine in the division of gastroenterology and hepatology at the Mayo Clinic in Rochester, Minn., and colleagues wrote that previous research has shown that Entyvio (vedolizumab, Takeda) therapy was effective and well-tolerated up to 1 year in patients with ulcerative colitis or Crohn’s disease.“The GEMINI long-term safety study continued assessment of patients treatedRead More

Share on facebook
Share on twitter
Share on linkedin